<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02172885</url>
  </required_header>
  <id_info>
    <org_study_id>EudraCT Number:2012-002553-38</org_study_id>
    <secondary_id>Health Department of Spain</secondary_id>
    <nct_id>NCT02172885</nct_id>
  </id_info>
  <brief_title>Mesenchymal Stem Cell Based Therapy for the Treatment of Osteogenesis Imperfecta</brief_title>
  <acronym>TERCELOI</acronym>
  <official_title>Mesenchymal Stem Cell Based Therapy for the Treatment of Osteogenesis Imperfecta</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital de Cruces</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospital Universitario Getafe</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Infantil Universitario Niño Jesús, Madrid, Spain</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital de Cruces</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and effectiveness of five infusions of
      characterized HLA-identical MSC in non immunosuppressed children with Osteogenesis Imperfecta
      (OI).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The principal aim of this trial is to assess the safety of non-mutated HLA-identical
      Mesenchymal stem cell (MSC) transplantation for OI pediatric patients irrespective of
      treatment with biphosphonates. Since MSC are inherently non-immunogenic and do not elicit
      proliferation of allogeneic lymphocytes (in co-culture experiments), a cell therapy based on
      HLA-identical or histocompatible (at least 5 shared out of 6 HLA antigens) allogenic MSC may
      be accomplished without subjecting the patients to immunosuppressor treatment. Adverse
      secondary effects due to immunosuppressor treatment will be avoided using this strategy thus
      patients may benefit from two cellular infusions. The patients will be followed for 2 years
      post their fifth and last MSC infusion.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events as a Measure of Safety</measure>
    <time_frame>up to 2 years post last MSCs infusion</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>bone mineral density</measure>
    <time_frame>up to 2 years post last MSCs infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fracture rate</measure>
    <time_frame>up to 2 years post last MSCs infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>growth velocity</measure>
    <time_frame>up to 2 years post last MSCs infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change from baseline in degree of functionality</measure>
    <time_frame>up to 2 years post last MSCs infusion</time_frame>
    <description>9 question survey using a Bleck functional scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change from baseline in well-being</measure>
    <time_frame>up to 2 years post last MSCs infusion</time_frame>
    <description>A 20 item questionnaire designed to evaluate the well-being will be used</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">5</enrollment>
  <condition>Osteogenesis Imperfecta</condition>
  <arm_group>
    <arm_group_label>Mesenchymal stem cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Five Mesenchymal Stem Cell infusions</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Mesenchymal Stem Cells</intervention_name>
    <description>Mesenchymal Stem Cell Infusions</description>
    <arm_group_label>Mesenchymal stem cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient age: older than 6 months and younger than 12 years old.

          -  Patients with molecular confirmation of mutation in either COL1A1 or COL1A2 genes
             associated with OI (type III).

          -  Patients with HLA identical (that shared at least 5/6 antigens) siblings willing to
             donate bone marrow-MSCs.

          -  All patients that fulfil the inclusion criteria regardless of whether or not they are
             undergoing biphosphonate treatment.

          -  Patients whose parents or the legal guardians are willing to sign the consent forms to
             participate in this clinical trial.

        Exclusion Criteria:

          -  Patient age: older than 12 years old

          -  Patients lacking confirmation of mutation in either COL1A1 or COL1A2 genes associated
             with severe deforming OI (type III).

          -  Other pathological subtypes of OI.

          -  Patients lacking of HLA identical (that shared at least 5/6 antigens) siblings willing
             to donate bone marrow-MSCs.

          -  Immunodeficiencies and any other malignancies.

          -  Participation in other clinical trial.

          -  Any medical or psychiatric condition that in the researcher´s opinion could affect the
             patient´s ability to complete the trial or hamper the participation in the trial.

          -  Patients whose parents or the legal guardians do not sign the consent forms
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clara I. Rodríguez, Ph. D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>BioCruces Health Research Institute/Cruces University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Universitario Cruces</name>
      <address>
        <city>Barakaldo</city>
        <state>Bizkaia</state>
        <zip>48903</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Getafe</name>
      <address>
        <city>Getafe</city>
        <state>Madrid</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 12, 2014</study_first_submitted>
  <study_first_submitted_qc>June 23, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 24, 2014</study_first_posted>
  <last_update_submitted>February 22, 2018</last_update_submitted>
  <last_update_submitted_qc>February 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital de Cruces</investigator_affiliation>
    <investigator_full_name>Clara I. Rodríguez</investigator_full_name>
    <investigator_title>PI Stem Cell Laboratory</investigator_title>
  </responsible_party>
  <keyword>Mesenchymal stem cell based therapy</keyword>
  <keyword>cell infusion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteogenesis Imperfecta</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

